Tandem Diabetes Care, Inc.
NASDAQ•TNDM
CEO: Mr. John F. Sheridan
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2013-11-14
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Contact Information
Market Cap
$1.70B
P/E (TTM)
-8.2
26.3
Dividend Yield
--
52W High
$29.65
52W Low
$9.98
52W Range
Rank61Top 91.5%
2.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$290.38M+0.00%
4-Quarter Trend
EPS
-$0.01+0.00%
4-Quarter Trend
FCF
$3.10M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Total Sales Growth Total sales reached $1.01B USD in 2025, marking a 7.9% increase over 2024 sales of $940.2M USD.
Gross Margin Expansion Gross margin improved to 54% in 2025, up from 52% in 2024, driven by better pricing and lower costs.
Major Litigation Settlement Recorded $20.0M litigation expense settling Roche Cross-License Agreement; IPR&D expense was $75.2M.
Risk Factors
Sustained Operating Losses Operating loss widened to $187.3M USD in 2025 from $99.1M USD in 2024 due to increased operating expenses.
Reimbursement Coverage Uncertainty Failure to secure adequate third-party payor coverage or reimbursement limits product acceptance and sales growth potential.
Supply Chain Dependency Risk Reliance on limited third-party suppliers for critical components risks supply continuity and harms business operations.
Cybersecurity Threat Exposure Systems vulnerable to cyberattacks, potentially causing data loss, operational disruption, and reputational harm across global operations.
Outlook
Pharmacy Channel Strategy Shift Implementing pay-as-you-go pharmacy benefit model in 2026 to increase adoption, offsetting initial decrease in pump sales.
Pipeline Innovation Focus Future technology includes tubeless patch pump option for Mobi and next-generation platform advancement for fully closed loop.
International Direct Sales Transition Transitioning international distribution to direct sales starting in UK and Austria during 2026 to enhance control.
Managing High Operating Costs Future capital needs depend on managing expenses related to R&D, sales expansion, and facility footprint growth.
Peer Comparison
Revenue (TTM)
$1.88B
$1.64B
$1.01B
Gross Margin (Latest Quarter)
91.3%
90.9%
86.7%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| TNGX | $2.26B | -22.2 | -50.3% | 8.4% |
| TNDM | $1.70B | -8.2 | -142.0% | 64.0% |
| IRMD | $1.27B | 56.4 | 23.8% | 0.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
7.4%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention
Deep Research
Next earnings:Apr 28, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data